STAT July 25, 2024
Andrew Joseph

LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental medicines that sent the company’s shares up — and those of its rivals down.

But on Thursday, company executives faced an onslaught of questions from analysts during an earnings presentation about what could come next for the company’s weight loss drugs and how they...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article